Australia markets close in 2 hours 34 minutes
  • ALL ORDS

    6,701.90
    -58.70 (-0.87%)
     
  • ASX 200

    6,501.20
    -53.80 (-0.82%)
     
  • AUD/USD

    0.6495
    -0.0009 (-0.14%)
     
  • OIL

    81.15
    -0.08 (-0.10%)
     
  • GOLD

    1,670.50
    +1.90 (+0.11%)
     
  • BTC-AUD

    29,871.77
    -234.93 (-0.78%)
     
  • CMC Crypto 200

    443.16
    -2.82 (-0.63%)
     
  • AUD/EUR

    0.6621
    +0.0005 (+0.08%)
     
  • AUD/NZD

    1.1349
    +0.0010 (+0.08%)
     
  • NZX 50

    11,023.82
    -176.22 (-1.57%)
     
  • NASDAQ

    11,164.78
    -329.05 (-2.86%)
     
  • FTSE

    6,881.59
    -123.80 (-1.77%)
     
  • Dow Jones

    29,225.61
    -458.13 (-1.54%)
     
  • DAX

    11,975.55
    -207.73 (-1.71%)
     
  • Hang Seng

    17,161.36
    -4.51 (-0.03%)
     
  • NIKKEI 225

    25,979.75
    -442.30 (-1.67%)
     

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

·4-min read

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

Given this risk, we thought we'd take a look at whether Anavex Life Sciences (NASDAQ:AVXL) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for Anavex Life Sciences

How Long Is Anavex Life Sciences' Cash Runway?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at June 2022, Anavex Life Sciences had cash of US$153m and no debt. In the last year, its cash burn was US$28m. So it had a cash runway of about 5.5 years from June 2022. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Anavex Life Sciences' Cash Burn Changing Over Time?

Because Anavex Life Sciences isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. As it happens, the company's cash burn reduced by 3.8% over the last year, which suggests that management are maintaining a fairly steady rate of business development, albeit with a slight decrease in spending. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For Anavex Life Sciences To Raise More Cash For Growth?

Even though it has reduced its cash burn recently, shareholders should still consider how easy it would be for Anavex Life Sciences to raise more cash in the future. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of US$925m, Anavex Life Sciences' US$28m in cash burn equates to about 3.0% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

Is Anavex Life Sciences' Cash Burn A Worry?

As you can probably tell by now, we're not too worried about Anavex Life Sciences' cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Its weak point is its cash burn reduction, but even that wasn't too bad! After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Taking a deeper dive, we've spotted 3 warning signs for Anavex Life Sciences you should be aware of, and 1 of them is potentially serious.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here